Receptor-peptide radionuclide therapy, most commonly referred to as PRRT, is a form of targeted systemic radiotherapy in which a molecule that binds to a specific receptor helps deliver the radioactive component to tissues that express the appropriate molecular target.
The best documented example discussed in this article is lutetium-177-labeled trastuzumab, used in selected patients with neuroendocrine tumors exhibiting somatostatin receptor expression.
PRRT is therefore not simply a general treatment method using peptides.
This is a precisely defined radiopharmaceutical approach, in which the targeting molecule, the radionuclide, the manner of their chemical binding, the formulation, the tumor characteristics, the receptor status, the conditions of therapy administration, and the safety procedures collectively influence the nature of the entire intervention.
This distinction is particularly important because the term „peptide therapy” is also widely used in marketing related to wellness, longevity, regeneration, or improved performance.
PRRT should not be automatically classified into the same category.
The clinical evidence relates to specific radiopharmaceutical drugs, selected patient populations with cancer, controlled clinical trials, specialized administration, radiological protection procedures, and structured medical monitoring.
The fact that a recognized therapeutic method for oncology includes a peptide-based guiding element does not constitute evidence of the efficacy of the peptides or products not associated with it.
The word „peptide” describes a specific molecular characteristic.
This does not mean that all interventions involving peptides have a common body of clinical evidence.
More information about the differences between the individual applications of peptides and approved medicinal products can be found in the article about approved peptide drugs.
What does this treatment method mean?
The peptide carries the radioactive component
The agent used in PRRT combines a molecule capable of recognizing a specific biological target with a radionuclide capable of delivering therapeutic radiation.
The peptide is responsible for recognizing the receptor and directing the molecule to the appropriate target.
The radioactive component, on the other hand, delivers radiation capable of damaging nearby cells after the radiopharmaceutical has accumulated in the appropriate tissue.
In the case of lutetium-177 radiotracers, the targeting moiety is linked to somatostatin, a naturally occurring signaling peptide.
However, a complete radiopharmaceutical should not be considered a substitute for natural somatostatin.
The medicinal product is a specially manufactured molecular structure with its own pharmacological, radiological, chemical and quality properties.
The identity of the peptide is important.
The significance of the radionuclide is important.
The way in which the radionuclide is chemically attached is important.
The formulation and control of the production process are important.
All these elements together determine the characteristics of complete therapy.
Therefore, describing PRRT solely as „the use of a peptide against cancer” overlooks several scientifically relevant elements of this intervention.
Systemic administration and molecular targeting
PRRT is a therapy administered systemically.
After administration, the radiopharmaceutical travels with the bloodstream and can reach tissues in different parts of the body.
This is different from external beam radiotherapy, in which the radiation is directed from the outside of the body to a specific anatomical area.
The guiding element in PRRT is to increase the delivery of the radiopharmaceutical to tissues that express the appropriate receptor.
„Targeted” does not, however, mean „exclusive”.
The radiopharmaceutical does not have to reach only the tumor tissue.
Its uptake, distribution, metabolism, elimination, and exposure in normal organs remain important elements of therapy planning and safety assessment.
The EMA describes lutetium-177 oxodotreotide as a compound that binds to somatostatin receptors present in the respective tumors and emphasizes that the drug is administered by qualified personnel under controlled clinical conditions.[1]
The targeting mechanism therefore increases biological specificity, but does not eliminate the need to take into account the distribution of the radiopharmaceutical throughout the body.
The name of the therapy does not specify all indications.
The term „neuroendocrine tumor” encompasses a biologically diverse group of tumors.
These tumors can arise in various anatomical locations and vary in degree of malignancy, differentiation, rate of proliferation, receptor expression, extent of disease, and clinical course.
Therefore, the results obtained in a single population of patients with neuroendocrine tumors should not be automatically applied to all neuroendocrine tumors.
The same principle applies to the radiopharmaceutical itself.
The approval of one radiolabeled peptide for a specific indication does not mean that every peptide, isotope, receptor, type of tumor, or radiopharmaceutical combination has been clinically proven.
The proper clinical question therefore does not simply read:
„Does PRRT work in neuroendocrine tumors?”
A more precise question concerns whether a specific radiopharmaceutical has evidence relating to a patient whose tumor characteristics and clinical situation are sufficiently similar to the population studied and the indication in question.
This approach allows maintaining the link between the evidence and the population in which it was actually obtained.
PRRT is not a wellness therapy
PRRT includes ionizing radiation, assessment of the molecular target, specialized handling of the radiopharmaceutical, assessment of organ function, monitoring, and risk management associated with the treatment.
Its clinical target and infrastructure are therefore fundamentally different from the products advertised in the context of general wellness, regeneration, anti-aging, longevity, body composition or performance.
The existence of an approved radiopharmaceutical based on a peptide does not confirm the efficacy of peptide products unrelated to it.
Similarly, the fact that one peptide can recognize a receptor associated with cancer does not mean that the peptides as a whole group have anti-cancer effects.
The complete molecular structure and clinical context are important.
PRRT should therefore be understood as a specialized method of oncological treatment, and not as evidence supporting a broad category called „peptide therapy”.
Targeting receptors and radioactive labeling
Expression of receptors helps determine the effectiveness of therapy
The peptide targeted to the receptor requires the presence of an appropriate molecular target.
In a well-known pathway of somatostatin receptors, the assessment of receptor expression helps determine whether the tumor tissue contains a potentially useful target for the radiopharmaceutical.
However, labeling the tumor as a „receptor-positive” does not guarantee the benefits of treatment.
The level and distribution of receptor expression may vary.
The interpretation of the results may be influenced by the biology of the tumor, the extent of the disease, heterogeneity, proliferation, prior treatment, and other clinical factors.
Individual changes in the same patient can also behave differently.
One change may show strong uptake, while another is much weaker.
Therefore, when determining whether to treat, the entire picture of the disease is taken into account, and not just the positive result of one imaging test or one change.
The expression of receptors is an important element of evidence.
However, it does not constitute a complete prognosis of the response to treatment.
Imaging diagnostics and treatment are related, but they are not the same thing.
Targeted imaging directed at a specific receptor can show where the appropriate marker is accumulating.
This provides information about the presence and location of the target molecule.
Therapeutic radiopharmaceuticals use a similar targeting concept, but deliver radiation intended to achieve a therapeutic effect.
This connection between diagnosis and treatment is often referred to as teranostics.
The diagnostic element helps characterize the biological target and can support the qualification for therapy.
However, the positive result of the imaging test does not prove that every change will respond to treatment.
It should also not be assumed automatically that the diagnostic marker is chemically identical to the therapeutic radiopharmaceutical.
These compounds can differ in radionuclides and other properties.
The most important common element is a specific target pathway and a specific clinical context, rather than the assumption that diagnosis and therapy are the same thing.
Radionuclides fundamentally change the nature of interventions
A peptide without a radioactive component is not an equivalent of a radiolabeled drug used in PRRT.
The addition of a radionuclide fundamentally changes the nature of the intervention.
The radionuclide introduces properties related to radioactive decay, the type of emitted radiation, the physical half-life, tissue exposure, the method of handling the product, its storage, radiological protection, and disposal.
A chelator may also play an important role, helping to keep the radiometal within the molecular structure.
The stability and integrity of this structure influence the retention of the radiopharmaceutical after administration.
Therefore, PRRT cannot be accurately described as „an injection of a peptide that targets cancer cells”.
The treatment is a complete radiopharmaceutical.
The directing molecule performs one function.
The radionuclide performs another function.
The chemical architecture that combines these elements and the pharmaceutical formulation influence the overall product behavior.
Targeting does not eliminate the risk to healthy tissues
Molecular targeting can improve the relationship between the radiation delivered to the tumor tissue and the radiation reaching other tissues.
However, this does not mean that exposure to radiation outside the tumor becomes biologically irrelevant.
The radiopharmaceutical circulates in the body, and its distribution and elimination can lead to exposure of normal organs.
The product information reviewed indicated clinically significant risks related to, among other things, blood cell production, kidney and liver function, reproductive health, and other systems.[2]
These risks do not undermine the value of receptor targeting.
They explain, however, why molecular targeting is combined with appropriate patient qualification, supportive treatment, monitoring, and specialist supervision.
Therapy can be both targeted and have systemic significance.
The words „targeted” should therefore not be interpreted as „risk-free beyond the tumor”.
The amount of medicine and the absorbed dose of radiation are different concepts.
The amount of the radiopharmaceutical administered and the amount of radiation absorbed by a particular tissue are related to each other, but are not the same thing.
Radioactivity describes the decay of atomic nuclei.
The absorbed dose refers to the amount of energy of radiation deposited in the tissue.
Individual tumors and organs can therefore receive different doses of absorbed radiation, even though the same therapy is administered to the bloodstream.
Dosimetry deals with the distribution and absorption of radiation.
This is a specialized field that includes the radiopharmaceutical, the patient's anatomy and physiology, imaging or other measurement information, and the context of the therapy.
It should not be confused with a regular online peptide dosage calculator.
The fact that in both cases the word „dose” is used does not mean that the calculations are equivalent.
Radiopharmaceutical dosimetry concerns exposure to radiation, not simply the mass of a peptide or the volume of a fluid.
More about why the dosages and methods of administration of different peptide products cannot be automatically transferred between formulations is discussed in the article Dosage and reconstitution of peptides.
Clinical evidence depending on indication
NETTER-1 showed a significant outcome regarding progression-free survival
NETTER-1 provided important randomized evidence regarding lutetium-177 uptake in a specific population of patients with neuroendocrine tumors.
The original publication included 229 patients with advanced, progressive, well-differentiated central nervous system neuroendocrine tumors showing somatostatin receptor expression.
The study compared lutet-177 supplemented with octreotide-assisted treatment with a control group receiving octreotide at a higher dose.
After 20 months, the estimated progression-free survival was 65.2% in the lutetium-177-treated group compared with 10.8% in the control group.
The percentages of objective responses were 18% and 3%, respectively [3].
These results showed a significant treatment effect with respect to the endpoint related to disease progression in the selected study population.
However, these figures require careful interpretation.
The estimated progression-free survival at 65.2% does not mean that 65.2% participants were cured.
The patient can still live with the disease and meet the progression-free survival criterion if, according to the definition used in the study, no progression has occurred.
The result should not be automatically applied to all neuroendocrine tumors.
The study population was determined by factors such as the tumor location, the degree of differentiation, progression, and the presence of somatostatin receptors.
Evidence remains strongest when its interpretation respects those boundaries.
The final analysis of overall survival requires a separate interpretation.
Long-term follow-up in NETTER-1 also included an analysis of overall survival.
The final analysis showed a median overall survival of 48.0 months in the lutetium-177-treated group and 36.3 months in the control group.
The numerical difference was 11.7 months.
However, the statistical analysis did not show a significant difference in overall survival.
The reported gambling ratio was 0.84, with a 95% confidence interval of 0.60–1.17 and p = 0.30. [4]
This distinction should be maintained.
The study should not be summarized by stating that an increase in life expectancy of 11.7 months has been proven.
The mean values differed numerically, but the analysis of overall survival did not show this difference as statistically significant.
At the same time, the lack of statistical evidence of a significant advantage in overall survival does not invalidate the earlier result regarding progression-free survival.
These end points answer various questions.
Progressive-free survival refers to progression or death as defined in the study.
Total survival refers to death from any cause.
A balanced interpretation should therefore take into account both results, rather than choosing only the one that sounds more advantageous.
NETTER-2 studied another therapeutic area within the treatment pathway
NETTER-2 evaluated lutet-177 in another population of patients with neuroendocrine tumors and at a different stage of treatment.
The study included 226 patients with newly diagnosed, advanced, well-differentiated neuroendocrine gastrointestinal-pancreatic tumors with a higher G2 or G3 grade.
The eligible tumors had Ki-67 index values in the range of 10–55% and exhibited somatostatin receptor expression in target cells.
The median survival free from progression was 22.8 months in the lutetium-177-treated group with octreotide compared to 8.5 months in the control group.[5]
The primary endpoint was evaluated in an independent, blinded central radiological assessment, although the actual treatment assignment was clear.
The results expanded the evidence base to an earlier stage of treatment in a strictly defined population.
However, they should not be generalized to all G3 neuroendocrine tumors.
The stage alone does not determine the entire biology of the tumor.
Variability, the rate of proliferation, receptor status, anatomical origin, and other pathological and clinical characteristics are still important.
NETTER-2 therefore expands the scope of evidence while maintaining important limits regarding the population being studied.
Supplementary analyses are not independent clinical studies
The NETTER-2 publication of August 2026 presented previously planned subgroup analyses and post hoc analyses according to factors such as the degree and origin of the tumor.
These analyses can provide additional information about the results in different parts of the original study population.
However, they do not constitute a second, independently randomized study.
The participants come from the original NETTER-2 study.
This distinction is important because several publications based on a single randomized study are not equivalent to several independent replications.
The subgroup results should also be interpreted taking into account the size of the groups, whether the analysis was previously planned, statistical power, multiple comparisons, and the question that the analysis was intended to answer.
Consistent estimates in several subgroups can be informative.
However, they do not have to prove that the treatment effect is identical in every subgroup.
The supplementary analyses therefore expand the knowledge derived from the study, but do not change the origin of the original randomized population.
Different clinical results should be interpreted separately
Clinical studies can measure several different outcomes and should not be treated as mutually interchangeable.
| Result | What it measures | Which he himself does not prove |
|---|---|---|
| Progressive-free survival | Time to progression or death according to study definition | No cure nor confirmed overall survival benefit |
| Total survival | Time to death from any cause | The mechanism responsible for the result |
| An objective answer | Reduction of a tumor meeting specific criteria | Complete elimination of the disease |
| Stabilization of the disease | No progression over a specified period of assessment | Permanent control of the disease |
| Quality of life | Functioning or symptoms reported by the patient | The reduction of the tumor itself |
| Safety result | Adverse events observed during the study | Absence of rare or delayed threats |
The tumor does not have to shrink significantly in order for the patient not to experience progression of the disease for a certain period of time.
The stabilization of the disease can therefore be a clinically significant outcome even when the tumor does not meet the formal criteria for response.
Similarly, the patient's symptoms and quality of life can change regardless of all imaging results.
The imaging study measures one aspect of the disease.
The results reported by the patients measure something different.
The end points regarding survival answer other questions as well.
Distinguishing these results makes it easier to interpret the studies correctly.
Regulatory status and clinical trial results are related, but not the same thing
Clinical studies provide evidence.
Regulatory authorities assess this evidence under the relevant regulations and decide whether a given medicinal product can be approved for use in specific indications.
The content of the approved indication does not need to repeat every inclusion criterion in the study word by word.
Regulatory decisions do not have to be identical in different jurisdictions either.
In April 2024, the FDA expanded the US indication for lutetium-177 dofetilide to include pediatric patients aged 12 years and older with specific gastrointestinal-endocrine neuroendocrine tumors exhibiting somatostatin receptor expression.[6]
The decision took into account pharmacokinetic, dosimetric and safety data in adolescents, together with the extrapolation of the efficacy evidence obtained in adults, as well as the requirement for long-term safety in adolescents.
The EMA document analyzed for the purposes of this article describes the indication in adults for non-operative or metastatic, progressive, well-differentiated gastrointestinal-pancreatic neuroendocrine tumors G1–G2 showing somatostatin receptor expression.[1]
These examples show why the three types of documents should not be treated as equivalent:
publication from a clinical study,
approved product information,
and an individual recommendation from a specialist regarding treatment.
They are interconnected, but each of them performs a different function.
Patient qualification and safety issues requiring specialist care
First, the recognition and biology of the tumor
The qualification for PRRT begins with determining which disease is actually present.
It is not enough to simply define a change as a neuroendocrine tumor.
The location of the tumor, the degree of differentiation, the histological stage, proliferation, the extent of the disease, the expression of receptors, the nature of the progression, and the clinical course can all influence the interpretation of treatment options.
Histopathological examination provides information about the characteristics of the tumor.
Receptor imaging provides information about the molecular target.
These types of evidence complement each other, rather than replacing each other.
A strongly positive receptor imaging result does not replace knowledge about the pathology of the tumor.
Similarly, the pathology itself does not provide all the information required for qualification for receptor-targeted therapy.
The specialist team also takes into account previous therapies, available alternatives, symptoms, fitness status, the burden of the disease, and the treatment goals.
The additional result of the imaging study thus constitutes one element of a broader clinical assessment.
The function of the organs influences the planning of therapy
PRRT leads to exposure to the radiopharmaceutical not only in the tumor tissue.
Therefore, the condition of the normal organs and the hematopoietic system is of clinical importance.
Blood morphology and renal and hepatic function are elements of the pre-treatment assessment and monitoring.
Previous therapies and existing diseases can also affect the tolerance to treatment.
The product information indicates risks that include, among others, myelosuppression, renal toxicity, hepatotoxicity, hormonal breakthrough, hypersensitivity, and risks related to reproductive health.[2]
This information should not be converted into a list for self-qualification for therapy.
Their significance lies in explaining why qualification and monitoring require specialized assessment.
Two patients with seemingly similar tumors may have different treatment outcomes due to organ function, prior therapies, the extent of the disease, or other clinical characteristics.
The risk of delayed onset requires longer observation
Some side effects may not become apparent until many months or years have passed.
Therefore, short-term tolerance of therapy does not provide a complete picture of its long-term safety.
Longer observation is particularly important in the case of therapies that can affect tissues such as the bone marrow.
The final report of NETTER-1 noted a myelodysplastic syndrome in two of the 111 treated patients belonging to the safety assessment population.[4]
This is an observation regarding a specific study.
It should not be turned into a universal prediction regarding a specific person.
At the same time, this result shows why the risk of delayed onset remains significant even when treatment was well tolerated immediately after administration.
Previous treatments that affect the bone marrow and other individual factors can also influence the interpretation of the risk.
Long-term monitoring therefore provides information that cannot be obtained solely from short-term observations.
Supportive treatment is part of the intervention
The PRRT study assesses more than just the radiolabeled molecule itself.
Therapy is carried out as part of a broader program that includes specialized administration, monitoring, supportive measures, management of other medications, and procedures to limit or control the risks associated with the treatment.
The official product information, for example, describes the infusion of amino acids as an element of kidney protection during therapy.[1]
This is an important component of the specialized treatment pathway.
It should not be taken out of this context and transformed into a manual for self-use.
The general rule is that the evidence from a clinical trial concerns the intervention in the form in which it was actually conducted.
Separating the radiopharmaceutical from monitoring, supportive treatment, radiological protection procedures, and clinical infrastructure that constitute part of the evidence base would create a fundamentally different situation.
Radiation protection measures require individual recommendations
Because PRRT uses a therapeutic radionuclide, after treatment the patient may receive instructions to limit the unnecessary exposure of other people to radiation.
Details may depend on the radiopharmaceutical used, the administered activity, local regulations, the patient's home situation, clinical assessment, and the procedures used at the given facility.
The educational article therefore cannot specify a single universal time limit for contact restrictions or other radiological protection measures.
In an individual situation, the appropriate source of information is the written recommendations of the treatment team.
Questions regarding pregnancy, breastfeeding, fertility, contact with household members, and other issues related to radiation should also be discussed directly with the clinical team responsible for the treatment.
The need for individual recommendations is not an inconvenience.
This is due to the fact that radiological protection is part of a specific clinical procedure, and not a general recommendation regarding the use of peptides.
Useful questions during consultations with a specialist
The specialist consultation should combine evidence from entire populations with the situation of a specific patient.
It is worth explaining why a given tumor was considered a suitable molecular target, which clinical evidence best corresponds to the specific situation, what effect can realistically be expected, what alternative treatment methods exist, and what uncertainties remain.
The patient may also ask how the response to the treatment will be evaluated and what monitoring will be necessary.
It is also important to properly understand the language used to describe the expected benefits.
The probability of controlling the disease is not a guarantee of a cure.
The median survival free from progression from a clinical trial does not exactly predict how long a specific person will remain free from progression.
The percentage of objective responses does not mean that every person has the same probability of responding regardless of tumor characteristics and other clinical factors.
The goal of informed discussion is therefore to interpret the results of research within the context of an individual clinical picture, rather than to transform average population results into personal guarantees.
Frequently asked questions
1. Is PRRT the same as the peptide therapy offered as part of wellness?
No. PRRT is a strictly defined method of oncological treatment using a radiopharmaceutical targeted to a receptor. The evidence relates to specific radiopharmaceuticals, selected patient populations with tumors, specialized administration, controlled clinical trials, and structured monitoring. Products marketed as peptide wellness, regenerative, longevity-enhancing, or performance-enhancing therapies do not automatically share the same evidence base. The fact that in both cases there are molecules identified as peptides does not imply equivalence in mechanism of action, quality, safety, or clinical efficacy.
2. Can every peptide target cancer receptors?
No. Binding to the receptor depends on the molecular structure of the peptide and the presence of the appropriate biological target. Many peptides do not have a defined role in targeting tumors. Even if a peptide can bind to a tumor-associated receptor, this by itself does not prove the effectiveness of anti-tumor therapy. In PRRT, the targeting peptide is only one component of a complete radiopharmaceutical, in which the radionuclide, chemical structure, formulation, distribution, and clinical evidence are also important.
3. What does the abbreviation PRRT mean?
PRRT stands for peptide receptor radionuclide therapy, which is a therapeutic approach in which a molecular element targeted to a receptor helps deliver a therapeutic radionuclide to tissues that express the target. PRRT is therefore a type of therapy rather than a single universal drug or treatment regimen. The specific radiopharmaceutical, receptor pathway, patient population, and approved indication still need to be determined.
4. Is PRRT chemotherapy?
PRRT is essentially classified as targeted radionuclide therapy rather than classic cytotoxic chemotherapy. Its therapeutic effect is based on ionizing radiation delivered through a molecular targeting system. However, this does not mean a lack of systemic adverse effects. Healthy tissues can also be exposed to radiation, which is why treatment requires appropriate monitoring. Clinical decisions therefore compare PRRT with appropriate therapeutic alternatives, rather than assuming that a particular treatment category is inherently risk-free.
5. Does a positive receptor test guarantee a response to treatment?
No. A positive result helps to identify the presence of a suitable molecular target, but does not guarantee a response to therapy. The result may be influenced by the level and distribution of receptor expression, the heterogeneity of the tumor, proliferation, the extent of the disease, prior treatment, the distribution of the radiopharmaceutical, and other clinical factors. Different changes in the same patient may also behave differently. Receptor imaging is therefore an important component of qualification, but is not a complete prognosis of treatment efficacy.
6. Are all neuroendocrine tumors equally suitable for PRRT?
No. Neuroendocrine tumors differ in anatomical location, differentiation, degree, rate of proliferation, receptor expression, extent of disease, and clinical course. NETTER-1 and NETTER-2 included strictly defined populations, not all neuroendocrine tumors. [3][5] The results of these studies should therefore remain relevant to the populations being studied. The mere recognition of a „neuroendocrine tumor” is not sufficient to determine whether a given form of PRRT is appropriate.
7. Does progression-free survival mean cure?
No. Progression-free survival defines the time during which a patient remains alive without meeting the disease progression definition adopted in the study. The tumor may still be present throughout this period. The endpoint may therefore mean clinically significant control of the disease without its complete elimination. The outcome of progression-free survival should not be converted into a cure rate; the percentage given for a given time point should not be described as the percentage of patients in whom the tumor has disappeared.
8. Has NETTER-1 proven an increase in overall survival?
The final analysis of NETTER-1 did not show a statistically significant difference in overall survival. The median overall survival was numerically longer in the lutetium-177-treated group and was 48.0 months compared to 36.3 months; however, the hazard ratio, the confidence interval, and the p-value did not allow for a definitive statement of superiority in overall survival in this analysis. [4] This result should be presented together with the significant benefit in progression-free survival previously demonstrated, and not in place of it.
9. Does NETTER-2 apply to every G3 tumor?
No. NETTER-2 included well-differentiated neuroendocrine tumors of the gastrointestinal tract and pancreas that met specific proliferation and receptor expression criteria. [5] Grade G3 includes biological situations that may go beyond these criteria. Therefore, the results of NETTER-2 cannot be automatically extrapolated to every high-grade neuroendocrine tumor. When assessing the suitability of a specific case to the study population, differentiation, Ki-67 expression, receptor expression, anatomical origin, pathology, and broader clinical situation remain important.
10. Are subgroup analyses new clinical studies?
No. Subgroup analyses evaluate a portion of the participants in an existing study and provide additional information regarding the same data. They do not create a new, independently randomized population of patients. Their interpretation depends, among other things, on the size of the subgroup, the prior planning of the analysis, statistical power, and the number of comparisons performed. Many publications from a single study can significantly deepen our understanding of the data, but they should not be considered many independent randomized replications.
11. Does the receptor diagnostic test provide the same therapy?
No. Imaging and therapeutic radionuclide procedures have different goals and may use different radiopharmaceuticals. Receptor-targeted imaging can detect uptake and help determine the presence of an appropriate molecular target. Therapeutic PRRT uses similar targeting principles but is used to deliver radiation to elicit a therapeutic effect. The diagnostic result may therefore support a qualification for therapy, but does not itself provide the same radiation exposure or demonstrate that each observed change is responsive to treatment.
12. Does targeted therapy spare all healthy tissues?
No. Molecular targeting can increase the delivery of the radiopharmaceutical to tissues that express the appropriate receptor, but it does not eliminate exposure in healthy organs. The radiopharmaceutical circulates throughout the body, and its uptake and elimination mean that the safety of therapy is not limited solely to the tumor tissue. Therefore, monitoring and radiological protection procedures remain an element of PRRT. The term „targeted” describes biological selectivity rather than delivering radiation exclusively to the tumor.
13. Why are blood tests and monitoring of organ function necessary?
They help doctors assess the possibility of using the treatment and monitor its potential impact on normal tissues. Important issues include, among others, blood cell production and the function of the kidneys and liver, as well as other risks described in the product information. [2] A positive receptor assessment result does not eliminate these issues. Monitoring is therefore part of a complete specialized treatment pathway, not an optional addition after choosing a radiopharmaceutical.
14. Can side effects appear after many months or years?
Yes. Some clinically relevant treatment-related effects may manifest with significant delay. Long-term observation therefore provides information that cannot be obtained from the short-term tolerability alone. In NETTER-1, for example, myelodysplastic syndrome was observed in a small number of treated participants during longer follow-up. [4] This observation from a specific study does not allow predicting what will happen in a single patient, but it shows why the absence of direct complications is not a guarantee of a lack of delayed risk.
15. Does the approval of therapy in the United States mean the same indication in Europe?
No. Regulatory indications may vary between jurisdictions because regulatory authorities assess evidence under their own regulations and procedures. The FDA and EMA documents regarding lutetium-177 are sufficient to show differences in the wording of the indications and the populations covered by them.[1][6] Therefore, current local product information should be checked. Foreign approval, publication from a clinical trial, or general PRRT description should not automatically replace the appropriate local regulatory status.
16. Is PRRT suitable for self-administration?
No. PRRT is conducted as part of specialized care that includes handling of radiopharmaceuticals, patient assessment, supportive treatment, monitoring, and radiological protection procedures. It is fundamentally different from a conventional peptide product intended for self-administration. The clinical evidence supporting PRRT specifically involves this controlled treatment environment. Removing the radiopharmaceutical from this system would not replicate the interventions studied in clinical trials and described in the official product information.
17. What should the patient ask before undergoing treatment?
The patient may ask why their tumor was considered a suitable target, which clinical evidence best relates to their situation, what effect can be realistically expected, what alternative treatment methods are available, and what short- and long-term risks require monitoring. It is also worth explaining how the response is assessed, the scope of adjuvant treatment, the plan for further observation, and the applicable radiological protection measures. The discussion should clearly separate the results regarding the entire population from the individual prognosis, because median survival and response rates do not allow for an accurate prediction of the course of the disease in a single person.
Summary
Peptide receptor radionuclide therapy combines molecular receptor targeting with therapeutic radiation.
The peptide-based targeting element helps deliver the radionuclide to tissues that express the appropriate receptor, but the complete intervention is the radiopharmaceutical, not the peptide itself.
The clinical significance therefore depends on the targeting molecule, radionuclide, chemical structure, formulation, tumor biology, receptor expression, patient characteristics, adjuvant therapy, monitoring, and the specialized therapeutic environment.
Controlled studies provided important evidence regarding selected populations of patients with neuroendocrine tumors.
NETTER-1 demonstrated a significant benefit in progression-free survival in patients with advanced, progressive, well-differentiated intermediate-gut neuroendocrine tumors showing somatostatin receptor expression. [3]
A subsequent analysis of overall survival showed a numerical difference in the median, but did not confirm a statistically significant benefit in overall survival.[4]
NETTER-2 subsequently demonstrated a significant progression-free survival outcome at another earlier site of the treatment pathway, involving strictly defined, well-differentiated gastrointestinal-pancreatic neuroendocrine tumors of higher grade. [5]
These results should remain related to the populations and endpoints that were actually studied.
Progressive-free survival does not mean cure.
An objective response does not mean the complete elimination of the disease.
The stabilization of the disease does not mean permanent control.
The numerical difference in overall survival is not automatically evidence of an advantage in terms of survival.
The receptor status does not guarantee a response to treatment.
Maintaining these distinctions allows clinical evidence to be presented in an informative manner, without going beyond what the studies actually showed.
The qualification of the patients is equally important.
Neuroendocrine tumors differ in location, degree, differentiation, proliferation, receptor expression, extent of disease, and clinical course.
Imaging techniques provide important information, but they do not replace pathological evaluation or broader clinical assessment.
The decision is also influenced by the function of the organs, previous treatment, available alternatives, symptoms, the goals of therapy, and the possibility of the occurrence of delayed adverse effects.
The safety system is part of the treatment itself.
PRRT uses ionizing radiation and can lead to exposure of both cancerous and normal tissues.
Monitoring of blood morphology and organ function, supportive measures, radiological protection, and long-term observation therefore constitute an element of a evidence-based clinical pathway.
The necessity of these measures does not contradict the idea of targeted therapy.
It, however, reflects the difference between preferential molecular targeting and complete tissue exclusion.
PRRT should also not be used as evidence for a broad commercial category sometimes referred to as „peptide therapy”.
Recognized peptide-based radiopharmaceutical therapy, used in selected cancers, does not confirm the efficacy of unrelated peptides marketed in the context of wellness, regeneration, longevity, fitness, or other applications.
The evidence relates to the specific radiopharmaceutical, indication, patient population, clinical outcome, and specialized treatment conditions in which it was obtained.
Disclaimer
This article is for educational and scientific information purposes only. It explains the principles of peptide receptor radionuclide therapy, receptor targeting, radioactive labeling, interpretation of clinical test results, regulatory differences, patient qualification, and safety issues.
It does not determine whether a specific person qualifies for PRRT, does not recommend PRRT or other anti-cancer treatment, does not contain instructions for the dosage or administration of radiopharmaceuticals, does not set the time for the use of radiological protective measures and does not replace an individual oncological assessment or consultation in the field of nuclear medicine.
Clinical trial rates, median survival, response rates, and subgroup analyses describe populations studied under specific conditions. They should not be interpreted as precise predictions of what will happen to a particular patient.
Decisions regarding PRRT require an appropriately qualified oncology and nuclear medicine team that is familiar with the patient’s diagnosis, histopathological test results, receptor status, organ function, prior treatment, current clinical status, available alternatives, and the locally applicable product information.
Questions regarding eligibility for treatment, monitoring, supportive therapy, pregnancy, breastfeeding, fertility, radiological protection, adverse effects, or further observation should be discussed directly with the specialized clinical team responsible for care.
References
- European Medicines Agency. (n.d.). Lutathera: European public assessment report. Retrieved September 29, 2026, from https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera
- Advanced Accelerator Applications USA, Inc. (2024). Lutether (lutetium Lu 177 doped): Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=72d1a024-00b7-418a-b36e-b2cb48f2ab55
- Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., Bushnell, D., O’Dorisio, T. M., Baum, R. P., Kulkarni, H. R., Caplin, M., Lebtahi, R., Hobday, T., Delpassand, E., Van Cutsem, E., … Investigators of the NETTER-1 Trial. (2017). Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. The New England Journal of Medicine, 376(2), 125–135. https://doi.org/10.1056/NEJMoa1607427
- Strosberg, J. R., Caplin, M. E., Kunz, P. L., Ruszniewski, P. B., Bodei, L., Hendifar, A., Mittra, E., Wolin, E. M., Yao, J. C., Pavel, M. E., Grande, E., Van Cutsem, E., Seregni, E., Duarte, H., Gericke, G., Bartalotta, A., Mariani, M. F., Demange, A., Mutevelic, S., … Investigators of NETTER-1. (2021). 177Lu-dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. The Lancet Oncology, 22(12), 1752–1763. https://doi.org/10.1016/S1470-2045(21)00572-6
- Singh, S., Halperin, D., Myrehaug, S., Herrmann, K., Pavel, M., Kunz, P. L., Chasen, B., Tafuto, S., Lastoria, S., Capdevila, J., García-Burillo, A., Oh, D.-Y., Yoo, C., Halfdanarson, T. R., Falk, S., Folitar, I., Zhang, Y., Aimone, P., de Herder, W. W., … Investigators of the NETTER-2 Trial. (2024). [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): An open-label, randomised, phase 3 study. The Lancet, 403(10446), 2807–2817. https://doi.org/10.1016/S0140-6736(24)00701-3
- U.S. Food and Drug Administration. (2024, April 23). The FDA approves the use of lutetium Lu 177 for pediatric patients 12 years and older with GEP-NETS. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-dotatate-pediatric-patients-12-years-and-older-gep-nets